Variation of bcl-2 expression in breast ducts and lobules in relation to plasma progesterone levels: Overexpression and absence of variation in fibroadenomas

Journal of Pathology

Volumn 183, Issue 2, 1997, Pages 204-211

  Ferrières, Gaëlle ^a   Cuny, Marguerite ^a,b   Simony Lafontaine, Joëlle ^a   Jacquemier, Jocelyne ^c   Rouleau, Caroline ^b   Guilleux, Françoise ^a   Grenier, Jean ^a   Rouanet, Philippe ^a   Pujol, Henri ^a   Jeanteur, Philippe ^a,b   Escot, Chantal ^a,b  

^a CENTRE VAL D AURELLE   (France)

^b CNRS   (France)

^c INSTITUT PAOLI CALMETTES   (France)

Author keywords

Adenosis; bcl 2; Cyst; Fibroadenoma; Hyperplasia; Mastopathies; Progesterone; Steroid hormones

Indexed keywords

PROGESTERONE; PROTEIN BCL 2; STEROID HORMONE;

APOPTOSIS; ARTICLE; BREAST CYST; BREAST DUCT; BREAST FIBROADENOMA; BREAST HYPERPLASIA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL;

BREAST NEOPLASMS; FEMALE; FIBROADENOMA; GONADAL STEROID HORMONES; HUMANS; IMMUNOENZYME TECHNIQUES; MENSTRUAL CYCLE; NEOPLASM PROTEINS; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 1842375641     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199710)183:2<204::AID-PATH921>3.0.CO;2-M     Document Type: Article

References (32)

1. Haagensen CD. Diseases of the Breast. Philadelphia: W. B. Saunders, 1986.
2. Adnane J, Gaudray P, Simon MP, et al. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989; 4: 1389-1395.
3. Ferguson DJP, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the 'resting' human breast. Br J Cancer 1981; 44: 177-181.
4. Walker NI, Bennett RE, Kerr JFR. Cell death by apoptosis during involution of the lactating breast in mice and rats. Am J Anat 1989; 185: 19-32.
5. Hoffman B, Liebermann DA. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 1994; 9: 1807-1812.
6. Hockenbery DM. bcl-2 in cancer, development and apoptosis. J Cell Sci 1994; 18: 51-55.
7. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
8. Lu QL, Elia G, Lucas S, Thomas JA. bcl-2 protooncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53: 29-35.
9. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690-694.
10. Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 1994; 9: 3367-3370.
11. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma. Association with ER-positive EGFR-negative tumors and in situ cancer. Br J Cancer 1994; 69: 135-139.
12. Doglioni C, Dei Toss AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathologic correlates, with particular reference to estrogen receptor status. Virchows Arch 1994; 424: 47-51.
13. Nathan B, Anbazhagan R, Dyer M, Ebbs SR, Jayatilake H, Gusterson BA. Expression of bcl-2-like immunoreactivity in the normal breast and in breast cancer. Breast 1993; 2: 134-137.
14. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
15. Nathan B, Gusterson B, Jadayel D, et al. Expression of bcl-2 in primary breast cancer and its correlation with tumor phenotype. Ann Oncol 1994; 5: 409-414.
16. Landgren BM, Linden AL, Diczfaluzy AG. Hormonal profile of the cycle in 68 normal menstruating women. Acta Endocrinol 1980; 94: 89-98.
17. Maudelonde T, Brouillet JP, Roger P, Giraudier V, Pàges A, Rochefort H. Immunostaining of cathepsin D in breast cancer quantified by computerized image analysis and correlation with cytosolic assay. Eur J Cancer 1992; 28A: 1686-1691.
18. Hawkins DM, Kass GV. Automatic interaction detection. In: Hawkins DG, ed. Topics in Applied Multivariate Analysis. Cambridge: Cambridge University Press, 1982.
19. Kass GV. An exploratory technique for investigating large quantities of categorical data. Appl Statistics 1980; 29: 119-127.
20. Trojani. Atlas en Couleurs d'Histopathologie Mammaire. Paris: Maloine, 1988.
21. Dupont WD, Page DL, Parl FF, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994; 331: 10-15.
22. Sabourin JC, Martin A, Baruch J, Truc JB, Gompel A, Poitout P. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994; 59: 1-6.
23. Allan DJ, Howell A, Roberts SA, et al. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 1992; 167: 25-32.
24. Escot C, Simony-Lafontaine J, Maudelonde T, Puech C, Pujol H, Rochefort H. Potential value of increased MYC but not ERBB2 RNA levels as a marker of high-risk mastopathies. Oncogene 1993; 8: 969-974.
25. Wang TTY, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 1995; 55: 2487-2489.
26. Page DL, Dupont WD. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990; 66: 1326-1335.
27. Morrow M. Pre-cancerous breast lesions: implications for breast cancer prevention trials. Int J Radiation Oncol 1992; 23: 1071-1078.
28. Hutchinson WB, Thomas DB, Hamlin WB, Roth GJ. Peterson AV, Williams B. Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst 1980; 65: 13-20.
29. Moskowitz M, Gartside P, Wirman JA, McLaughlin C. Proliferative disorders of the breast as risk factors for breast cancer in a self-selected screened population: pathologic markers. Radiology 1980; 134: 289-291.
30. Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. Am J Epidemiol 1988; 128: 467-477.
31. McDivitt RW, Stevens JA, Lee NC, Wingo PA, Rubin GL, Gersell D. Histologic types of benign breast disease and the risk for breast cancer. Cancer 1992; 69: 1408-1414.
32. Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases: variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992; 135: 619-631.